Third-line Hormonal Therapy to Treat Prostate Cancer Relapse after Initial and Second-line Hormonal Therapy: Report of 52 Cases and Literature Review

Matsumoto, Kazuhiro; Hagiwara, Masayuki; Hayakawa, Nozomi; Tanaka, Nobuyuki; Ito, Yujiro; Maeda, Takahiro; Ninomiya, Akiharu; Nagata, Hirohiko; Nakamura, So

추천

검색

자료유형: 학술저널

저자정보: Matsumoto, Kazuhiro (Department of Urology, Tokyo Saiseikai Central Hospital) Hagiwara, Masayuki (Department of Urology, Tokyo Dental College Ichikawa General Hospital) Hayakawa, Nozomi (Department of Urology, Tokyo Saiseikai Central Hospital) Tanaka, Nobuyuki (Department of Urology, Saitama Municipal Hospital) Ito, Yujiro (Department of Urology, Tokyo Saiseikai Central Hospital) Maeda, Takahiro (Department of Urology, Tokyo Saiseikai Central Hospital) Ninomiya, Akiharu (Department of Urology, Tokyo Saiseikai Central Hospital) Nagata, Hirohiko (Department of Urology, Tokyo Saiseikai Central Hospital) Nakamura, So (Department of Urology, Tokyo Saiseikai Central Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제8호

발행연도: 2014.1

수록면: 3,645 - 3,649 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English. Including our cases, this provided a total of 102 cases for analysis. In our study cohort, 11 cases (21.2%) achieved more than 50% reduction of serum prostate-specific antigen (PSA) on initiation of third-line CAB. We found that third-line CAB with nonsteroidal antiandrogen after second-line CAB with steroidal antiandrogen exhibited favorable results, with a positive response in six of 13 patients (46.2%). Cumulative analysis findings were comparable. Regarding the timing of third-line CAB administration, 15 patients had started at a PSA equal to or less than 4.0 ng/ml, and eight of them (53.3%) showed a positive response to treatment, compared to only three of 37 patients (8.1%) whose PSA at the initiation of third-line therapy was higher than 4.0 ng/ml (p<0.001). We conclude that third-line CAB with nonsteroidal antiandrogen would be particularly useful for patients whose cancer progressed after second-line CAB with steroidal antiandrogen. The timing of treatment seems to be important because the higher the PSA at the start of third-line therapy, the lower the PSA response rate.

#prostate cancer #hormonal therapy #alternative antiandrogen #CRPC

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요